Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AstraZeneca beats Street EPS

AstraZeneca (LSE:AZN; AZN) reported second quarter EPS of $0.39, beating by $0.06 the Street's $0.33 consensus estimate. The EPS

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE